SYNTARA LIMITED - Announcements

Market Cap $28.65M Add to my watchlist

Healthcare

Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug... Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. It has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.More

Announcements

Filter Results

All Price Sensitive Only

SNT	EU Marketing Authorisation Application Review of Bronchitol	PRICE SENSITIVE	27/06/11	87.3KB	Share
SNT	EU CHMP Confirms Negative Trend Vote on Bronchitol	PRICE SENSITIVE	24/06/11	82.97KB	Share
SNT	Change in substantial holding		21/06/11	43.47KB	Share
SNT	Change in substantial holding		16/06/11	94.9KB	Share
SNT	Response to ASX Query Letter	PRICE SENSITIVE	31/05/11	112.01KB	Share
SNT	Change of Director's Interest Notice		27/05/11	24.31KB	Share
SNT	Change in substantial holding		27/05/11	91.71KB	Share
SNT	Ceasing to be a substantial holder		26/05/11	48.18KB	Share
SNT	Pharmaxis Receives Negative Bronchitol Trend Vote from CHMP	PRICE SENSITIVE	25/05/11	88.52KB	Share
SNT	Additional Background to Appendix 3Y Filed 18 May 2011		24/05/11	86.58KB	Share
SNT	Investor Conference Call		24/05/11	57.47KB	Share
SNT	Trading Halt	PRICE SENSITIVE	23/05/11	155.43KB	Share
SNT	Change of Director's Interest Notice		18/05/11	105.27KB	Share
SNT	Appendix 3B: Exercise of Employee Options		27/04/11	97.52KB	Share
SNT	Appendix 3B - Exercise of Employee Options		21/04/11	97.44KB	Share
SNT	Bronchitol Deferred by Australian PBAC	PRICE SENSITIVE	21/04/11	80.81KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	13/04/11	108.88KB	Share
SNT	Quarterly Report to Shareholders - March 2011		13/04/11	382.69KB	Share
SNT	Quarterly Investor Conference Call		12/04/11	21.6KB	Share
SNT	Becoming a substantial holder		16/03/11	227.73KB	Share
SNT	Becoming a substantial holder		03/03/11	53.89KB	Share
SNT	Ceasing to be a substantial holder		14/02/11	33.68KB	Share
SNT	Australian TGA Approves Bronchitol for Cystic Fibrosis	PRICE SENSITIVE	08/02/11	81.67KB	Share
SNT	Half Yearly Report and Accounts	PRICE SENSITIVE	04/02/11	161.09KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	25/01/11	108.89KB	Share
SNT	Quarterly Report to Shareholders		25/01/11	420.74KB	Share
SNT	EU Bronchitol Marketing Application Update	PRICE SENSITIVE	25/01/11	77.59KB	Share
SNT	Appendix 3B - Grant of Employee Options		25/01/11	98.58KB	Share
SNT	Quarterly Investor Report and Conference Call		24/01/11	21.69KB	Share
SNT	Disclosure notice under section 708A(5) of Corporations Act		19/01/11	46.84KB	Share
SNT	Appendix 3B		19/01/11	120.55KB	Share
SNT	Becoming a substantial holder		14/01/11	54.95KB	Share
SNT	Appendix 3B - Exercise of Employee Options		12/01/11	97.44KB	Share
SNT	Appendix 3B - Exercise of Employee Options		21/12/10	97.44KB	Share
SNT	Share Trading Policy		21/12/10	158.53KB	Share
SNT	Bronchitol EU Marketing Authorisation Update	PRICE SENSITIVE	20/12/10	78.68KB	Share
SNT	Extended Benefit with Bronchitol in Second PhaseIII CF Trial	PRICE SENSITIVE	16/12/10	80.73KB	Share
SNT	Pharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol		15/12/10	68.12KB	Share
SNT	Ceasing to be a substantial holder		14/12/10	44.97KB	Share
SNT	Bronchitol Recommended for Approval by Australian Advisory C	PRICE SENSITIVE	13/12/10	225.12KB	Share
SNT	Phase II Trial of ASM8 in Asthma Commences	PRICE SENSITIVE	07/12/10	91.42KB	Share
SNT	Appendix 3B - Exercise of Employee Options		30/11/10	97.47KB	Share
SNT	Appendix 3B - Exercise of Employee Options		25/11/10	97.41KB	Share
SNT	Change of Director's Interest Notice		25/11/10	14.4KB	Share
SNT	Appendix 3B Exercise of Employee Options		16/11/10	97.47KB	Share
SNT	Appendix 3B - Grant of Employee Performance Rights		15/11/10	97.43KB	Share
SNT	Updated Investor Presentation		09/11/10	2.47MB	Share
SNT	Appendix 3B - Exercise of Employee Options		08/11/10	97.54KB	Share
SNT	APpendix 3B - Exercise of Employee Options		02/11/10	97.5KB	Share
SNT	Appendix 3B - Exercise of Employee Options		28/10/10	97.49KB	Share
SNT	Appendix 3B - Exercise of Employee Options		22/10/10	97.43KB	Share
SNT	Pharmaxis Announces Positive Combined Phase 3 CF Results	PRICE SENSITIVE	22/10/10	90.37KB	Share
SNT	Becoming a substantial holder		21/10/10	56.02KB	Share
SNT	Change of Director's Interest Notice		20/10/10	14.45KB	Share
SNT	Results of Meeting		20/10/10	82.42KB	Share
SNT	Appendix 3B - Option Issue		20/10/10	97.13KB	Share
SNT	CEO Presentation to 2010 AGM		20/10/10	2.52MB	Share
SNT	Chairman's Address to 2010 AGM		20/10/10	29.76KB	Share
SNT	Pharmaxis CEO Resumes Office		20/10/10	20.51KB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	13/10/10	109.71KB	Share
SNT	Quarterly Report to Shareholders		13/10/10	363.92KB	Share
SNT	Quarterly Investor Conference Call		12/10/10	21.68KB	Share
SNT	Becoming a substantial holder		12/10/10	115.47KB	Share
SNT	US FDA APPROVES ARIDOL	PRICE SENSITIVE	06/10/10	82.52KB	Share
SNT	Appendix 3B - grant of employee equity		27/09/10	96.3KB	Share
SNT	Notice of 2010 Annual General Meeting/Proxy Form		10/09/10	451.23KB	Share
SNT	Pharmaxis 2010 Annual Review		10/09/10	843.31KB	Share
SNT	Statutory Annual Report		10/09/10	394.32KB	Share
SNT	Proposed issue of options to CEO		08/09/10	80.42KB	Share
SNT	Appendix 3B - annual grant of employee options		08/09/10	95.31KB	Share
SNT	Agreement for European Marketing of Bronchitol	PRICE SENSITIVE	31/08/10	77.65KB	Share
SNT	Exercise of Employee Options		27/07/10	96.4KB	Share
SNT	Quarterly Report to Shareholders - June 2010		21/07/10	1.92MB	Share
SNT	Appendix 4C - quarterly	PRICE SENSITIVE	21/07/10	110.79KB	Share
SNT	Quarterly Investor Conference Call Details		20/07/10	21.64KB	Share
SNT	Update on Pharmaxis CEO		08/07/10	127.25KB	Share
SNT	Ceasing to be a substantial holder		25/06/10	49.32KB	Share
SNT	Updated Investor Presentation		24/06/10	2.54MB	Share
SNT	Results for Second Phase 3 Trial of Bronchitol in CF	PRICE SENSITIVE	22/06/10	94.43KB	Share
SNT	Investor Conference Call - Clinical Trial Results		22/06/10	21.64KB	Share
SNT	Trading Halt	PRICE SENSITIVE	21/06/10	93.7KB	Share
SNT	Pharmaxis CEO		18/06/10	20.95KB	Share
SNT	Exercise of Employee Options		31/05/10	96.29KB	Share
SNT	Sustained Benefit Following 18 Month Bronchitol Treatment	PRICE SENSITIVE	17/05/10	45.53KB	Share
SNT	Appendix 3B - Exercise of Employee Options		30/04/10	96.28KB	Share
SNT	Pharmaxis resubmission for Aridol US marketing application		27/04/10	87.28KB	Share
SNT	Appendix 3B - Exercise of Employee Options		23/04/10	96.32KB	Share
SNT	Change in substantial holding		22/04/10	80.7KB	Share
SNT	Appendix 4C - quarterly March 2010	PRICE SENSITIVE	14/04/10	116.43KB	Share
SNT	March 2010 Quarterly Report to Shareholders		14/04/10	428.91KB	Share
SNT	Pharmaxis Announces Milestone in Phase 3 Trial for CF	PRICE SENSITIVE	14/04/10	25.5KB	Share
SNT	PHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL		12/04/10	21.59KB	Share
SNT	Appendix 3B - Exercise of Employee Options		23/03/10	96.31KB	Share
SNT	Disclosure notice under section 708A(5)(e)		15/03/10	38.46KB	Share
SNT	Appendix 3B - Topigen Milestone Payment		15/03/10	95.04KB	Share
SNT	Pharmaxis Completes Phase II Clinical Study with ASM8	PRICE SENSITIVE	11/03/10	106.53KB	Share
SNT	Change in substantial holding		10/03/10	57.75KB	Share
SNT	Investor Presentation		02/03/10	2.66MB	Share
SNT	Disclosure notice under section 708A(5) of Corporations Act		09/02/10	38.42KB	Share
SNT	Appendix 3B - Topigen Acquisition		09/02/10	95.08KB	Share

SNTEU Marketing Authorisation Application Review of Bronchitol
27/06/11	PRICE SENSITIVE	87.3KB	Share
SNTEU CHMP Confirms Negative Trend Vote on Bronchitol
24/06/11	PRICE SENSITIVE	82.97KB	Share
SNTChange in substantial holding
21/06/11		43.47KB	Share
SNTChange in substantial holding
16/06/11		94.9KB	Share
SNTResponse to ASX Query Letter
31/05/11	PRICE SENSITIVE	112.01KB	Share
SNTChange of Director's Interest Notice
27/05/11		24.31KB	Share
SNTChange in substantial holding
27/05/11		91.71KB	Share
SNTCeasing to be a substantial holder
26/05/11		48.18KB	Share
SNTPharmaxis Receives Negative Bronchitol Trend Vote from CHMP
25/05/11	PRICE SENSITIVE	88.52KB	Share
SNTAdditional Background to Appendix 3Y Filed 18 May 2011
24/05/11		86.58KB	Share
SNTInvestor Conference Call
24/05/11		57.47KB	Share
SNTTrading Halt
23/05/11	PRICE SENSITIVE	155.43KB	Share
SNTChange of Director's Interest Notice
18/05/11		105.27KB	Share
SNTAppendix 3B: Exercise of Employee Options
27/04/11		97.52KB	Share
SNTAppendix 3B - Exercise of Employee Options
21/04/11		97.44KB	Share
SNTBronchitol Deferred by Australian PBAC
21/04/11	PRICE SENSITIVE	80.81KB	Share
SNTAppendix 4C - quarterly
13/04/11	PRICE SENSITIVE	108.88KB	Share
SNTQuarterly Report to Shareholders - March 2011
13/04/11		382.69KB	Share
SNTQuarterly Investor Conference Call
12/04/11		21.6KB	Share
SNTBecoming a substantial holder
16/03/11		227.73KB	Share
SNTBecoming a substantial holder
03/03/11		53.89KB	Share
SNTCeasing to be a substantial holder
14/02/11		33.68KB	Share
SNTAustralian TGA Approves Bronchitol for Cystic Fibrosis
08/02/11	PRICE SENSITIVE	81.67KB	Share
SNTHalf Yearly Report and Accounts
04/02/11	PRICE SENSITIVE	161.09KB	Share
SNTAppendix 4C - quarterly
25/01/11	PRICE SENSITIVE	108.89KB	Share
SNTQuarterly Report to Shareholders
25/01/11		420.74KB	Share
SNTEU Bronchitol Marketing Application Update
25/01/11	PRICE SENSITIVE	77.59KB	Share
SNTAppendix 3B - Grant of Employee Options
25/01/11		98.58KB	Share
SNTQuarterly Investor Report and Conference Call
24/01/11		21.69KB	Share
SNTDisclosure notice under section 708A(5) of Corporations Act
19/01/11		46.84KB	Share
SNTAppendix 3B
19/01/11		120.55KB	Share
SNTBecoming a substantial holder
14/01/11		54.95KB	Share
SNTAppendix 3B - Exercise of Employee Options
12/01/11		97.44KB	Share
SNTAppendix 3B - Exercise of Employee Options
21/12/10		97.44KB	Share
SNTShare Trading Policy
21/12/10		158.53KB	Share
SNTBronchitol EU Marketing Authorisation Update
20/12/10	PRICE SENSITIVE	78.68KB	Share
SNTExtended Benefit with Bronchitol in Second PhaseIII CF Trial
16/12/10	PRICE SENSITIVE	80.73KB	Share
SNTPharmaxis Holds Pre-NDA Meeting with FDA for Bronchitol
15/12/10		68.12KB	Share
SNTCeasing to be a substantial holder
14/12/10		44.97KB	Share
SNTBronchitol Recommended for Approval by Australian Advisory C
13/12/10	PRICE SENSITIVE	225.12KB	Share
SNTPhase II Trial of ASM8 in Asthma Commences
07/12/10	PRICE SENSITIVE	91.42KB	Share
SNTAppendix 3B - Exercise of Employee Options
30/11/10		97.47KB	Share
SNTAppendix 3B - Exercise of Employee Options
25/11/10		97.41KB	Share
SNTChange of Director's Interest Notice
25/11/10		14.4KB	Share
SNTAppendix 3B Exercise of Employee Options
16/11/10		97.47KB	Share
SNTAppendix 3B - Grant of Employee Performance Rights
15/11/10		97.43KB	Share
SNTUpdated Investor Presentation
09/11/10		2.47MB	Share
SNTAppendix 3B - Exercise of Employee Options
08/11/10		97.54KB	Share
SNTAPpendix 3B - Exercise of Employee Options
02/11/10		97.5KB	Share
SNTAppendix 3B - Exercise of Employee Options
28/10/10		97.49KB	Share
SNTAppendix 3B - Exercise of Employee Options
22/10/10		97.43KB	Share
SNTPharmaxis Announces Positive Combined Phase 3 CF Results
22/10/10	PRICE SENSITIVE	90.37KB	Share
SNTBecoming a substantial holder
21/10/10		56.02KB	Share
SNTChange of Director's Interest Notice
20/10/10		14.45KB	Share
SNTResults of Meeting
20/10/10		82.42KB	Share
SNTAppendix 3B - Option Issue
20/10/10		97.13KB	Share
SNTCEO Presentation to 2010 AGM
20/10/10		2.52MB	Share
SNTChairman's Address to 2010 AGM
20/10/10		29.76KB	Share
SNTPharmaxis CEO Resumes Office
20/10/10		20.51KB	Share
SNTAppendix 4C - quarterly
13/10/10	PRICE SENSITIVE	109.71KB	Share
SNTQuarterly Report to Shareholders
13/10/10		363.92KB	Share
SNTQuarterly Investor Conference Call
12/10/10		21.68KB	Share
SNTBecoming a substantial holder
12/10/10		115.47KB	Share
SNTUS FDA APPROVES ARIDOL
06/10/10	PRICE SENSITIVE	82.52KB	Share
SNTAppendix 3B - grant of employee equity
27/09/10		96.3KB	Share
SNTNotice of 2010 Annual General Meeting/Proxy Form
10/09/10		451.23KB	Share
SNTPharmaxis 2010 Annual Review
10/09/10		843.31KB	Share
SNTStatutory Annual Report
10/09/10		394.32KB	Share
SNTProposed issue of options to CEO
08/09/10		80.42KB	Share
SNTAppendix 3B - annual grant of employee options
08/09/10		95.31KB	Share
SNTAgreement for European Marketing of Bronchitol
31/08/10	PRICE SENSITIVE	77.65KB	Share
SNTExercise of Employee Options
27/07/10		96.4KB	Share
SNTQuarterly Report to Shareholders - June 2010
21/07/10		1.92MB	Share
SNTAppendix 4C - quarterly
21/07/10	PRICE SENSITIVE	110.79KB	Share
SNTQuarterly Investor Conference Call Details
20/07/10		21.64KB	Share
SNTUpdate on Pharmaxis CEO
08/07/10		127.25KB	Share
SNTCeasing to be a substantial holder
25/06/10		49.32KB	Share
SNTUpdated Investor Presentation
24/06/10		2.54MB	Share
SNTResults for Second Phase 3 Trial of Bronchitol in CF
22/06/10	PRICE SENSITIVE	94.43KB	Share
SNTInvestor Conference Call - Clinical Trial Results
22/06/10		21.64KB	Share
SNTTrading Halt
21/06/10	PRICE SENSITIVE	93.7KB	Share
SNTPharmaxis CEO
18/06/10		20.95KB	Share
SNTExercise of Employee Options
31/05/10		96.29KB	Share
SNTSustained Benefit Following 18 Month Bronchitol Treatment
17/05/10	PRICE SENSITIVE	45.53KB	Share
SNTAppendix 3B - Exercise of Employee Options
30/04/10		96.28KB	Share
SNTPharmaxis resubmission for Aridol US marketing application
27/04/10		87.28KB	Share
SNTAppendix 3B - Exercise of Employee Options
23/04/10		96.32KB	Share
SNTChange in substantial holding
22/04/10		80.7KB	Share
SNTAppendix 4C - quarterly March 2010
14/04/10	PRICE SENSITIVE	116.43KB	Share
SNTMarch 2010 Quarterly Report to Shareholders
14/04/10		428.91KB	Share
SNTPharmaxis Announces Milestone in Phase 3 Trial for CF
14/04/10	PRICE SENSITIVE	25.5KB	Share
SNTPHARMAXIS QUARTERLY INVESTOR CONFERENCE CALL
12/04/10		21.59KB	Share
SNTAppendix 3B - Exercise of Employee Options
23/03/10		96.31KB	Share
SNTDisclosure notice under section 708A(5)(e)
15/03/10		38.46KB	Share
SNTAppendix 3B - Topigen Milestone Payment
15/03/10		95.04KB	Share
SNTPharmaxis Completes Phase II Clinical Study with ASM8
11/03/10	PRICE SENSITIVE	106.53KB	Share
SNTChange in substantial holding
10/03/10		57.75KB	Share
SNTInvestor Presentation
02/03/10		2.66MB	Share
SNTDisclosure notice under section 708A(5) of Corporations Act
09/02/10		38.42KB	Share
SNTAppendix 3B - Topigen Acquisition
09/02/10		95.08KB	Share

REFRESH

First 6 7 8 9 10

(20min delay)
Last 2.4¢		Change 0.002(9.09%)		Mkt cap ! $28.65M

Open	High	Low	Value	Volume
2.2¢	2.5¢	2.2¢	$12.04K	509.9K

Buyers (Bids)

No.	Vol.	Price($)
1	82668	2.3¢

Sellers (Offers)

Price($)	Vol.	No.
2.4¢	100000	1

View Market Depth

No.	Vol.	Price($)
1	82668	0.023
2	338839	0.022
5	1736248	0.021
11	2801008	0.020
2	999988	0.019

Price($)	Vol.	No.
0.024	100000	1
0.025	100000	1
0.026	50000	1
0.027	200000	1
0.028	500000	1

Last trade - 15.57pm 28/06/2024 (20 minute delay)


Last 2.5¢		Change 0.002 ( 13.6 %)
Open	High	Low	Volume
2.2¢	2.5¢	2.2¢	478642
Last updated 15.53pm 28/06/2024 ?

SNT (ASX) Chart

SYNTARA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories